Chris Limberakis
Research Subjects
Chris Limberakis has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- David W. Piotrowski
Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
6 shared publications - Roger B. Ruggeri
Pfizer Medicine Design, Cambridge, MA 02139, United States
5 shared publications - David A. Griffith
Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
4 shared publications - Scott W. Bagley
Medicine Design, Pfizer Inc, Groton, USA
4 shared publications - Amit S. Kalgutkar
Medicine Design, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA
3 shared publications Liuqing Wei
Pfizer Research & Development , 445 Eastern Point Road
3 shared publications
Latest Publications
- 27 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (19) , 22942-22953
Discovery of Neutral and Cerebrospinal Fluid Penetrant Transthyretin (TTR) Stabilizers with Heterocyclic Linkers
Human transthyretin (TTR) is associated with ATTR amyloidosis. Despite having approved agents against TTR, there is still an unmet medical need to develop novel agents, especially those that could have therapeutic effects in cerebrospinal fluid (CSF). Structure-based drug design (SBDD) in the thyroxine binding pocket of TTR identified a neutral hit. Further optimization led to compound 9, a neutral TTR tetramer stabilizer with single-digit nM SPR Kd potency and with improved ADME profile that could enable it to penetrate to CSF.
- 27 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (19) , 22942-22953
Discovery of Neutral and Cerebrospinal Fluid Penetrant Transthyretin (TTR) Stabilizers with Heterocyclic Linkers
Human transthyretin (TTR) is associated with ATTR amyloidosis. Despite having approved agents against TTR, there is still an unmet medical need to develop novel agents, especially those that could have therapeutic effects in cerebrospinal fluid (CSF). Structure-based drug design (SBDD) in the thyroxine binding pocket of TTR identified a neutral hit. Further optimization led to compound 9, a neutral TTR tetramer stabilizer with single-digit nM SPR Kd potency and with improved ADME profile that could enable it to penetrate to CSF.
- 7 November 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 98, 129546
Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3
- 7 November 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 98, 129546
Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3
- 26 September 2023
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 88 (19) , 13727-13740
Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors
The synthesis of imidazole fused spirocyclic ketones as templates for acetyl-CoA carboxylase (ACC) inhibitors is reported. By completing the spirocyclic ring closure via divergent pathways, the synthesis of these regioisomers from common intermediates was developed. Through an aldehyde homologation/ transmetalation strategy, one isomer was formed selectively. The second desired isomer was obtained via an intramolecular aromatic homolytic substitution reaction. Preparation of these isomeric spiroketones provided templates which, upon elaboration, led to key structure-activity relationship (SAR) points for delivery of potent ACC inhibitors.
- 26 September 2023
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 88 (19) , 13727-13740
Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors
The synthesis of imidazole fused spirocyclic ketones as templates for acetyl-CoA carboxylase (ACC) inhibitors is reported. By completing the spirocyclic ring closure via divergent pathways, the synthesis of these regioisomers from common intermediates was developed. Through an aldehyde homologation/ transmetalation strategy, one isomer was formed selectively. The second desired isomer was obtained via an intramolecular aromatic homolytic substitution reaction. Preparation of these isomeric spiroketones provided templates which, upon elaboration, led to key structure-activity relationship (SAR) points for delivery of potent ACC inhibitors.
- 15 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 94, 129454
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor
- 15 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 94, 129454
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor
- 26 June 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 92, 129394
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups
- 26 June 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 92, 129394
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups
- Open Access
- 28 April 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (20) , 11173-11184
Bioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells
G protein-coupled receptors (GPCRs) modulate diverse cellular signaling pathways and are important drug targets. Despite the availability of high-resolution structures, the discovery of allosteric modulators remains challenging due to the dynamic nature of GPCRs in native membranes. We developed a strategy to covalently tether drug fragments adjacent to allosteric sites in GPCRs to enhance their potency and enable fragment-based drug screening in cell-based systems. We employed genetic code expansion to site-specifically introduce noncanonical amino acids with reactive groups in C-C chemokine receptor 5 (CCR5) near an allosteric binding site for the drug maraviroc. We then used molecular dynamics simulations to design heterobifunctional maraviroc analogues consisting of a drug fragment connected by a flexible linker to a reactive moiety capable of undergoing a bioorthogonal coupling reaction. We synthesized a library of these analogues and employed the bioorthogonal inverse electron demand Diels-Alder reaction to couple the analogues to the engineered CCR5 in live cells, which were then assayed using cell-based signaling assays. Tetherable low-affinity maraviroc fragments displayed an increase in potency for CCR5 engineered with reactive unnatural amino acids that were adjacent to the maraviroc binding site. The strategy we describe to tether novel drug fragments to GPCRs should prove useful to probe allosteric or cryptic binding site functionality in fragment-based GPCR-targeted drug discovery.
- 28 April 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (20) , 11173-11184
Open AccessBioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells
G protein-coupled receptors (GPCRs) modulate diverse cellular signaling pathways and are important drug targets. Despite the availability of high-resolution structures, the discovery of allosteric modulators remains challenging due to the dynamic nature of GPCRs in native membranes. We developed a strategy to covalently tether drug fragments adjacent to allosteric sites in GPCRs to enhance their potency and enable fragment-based drug screening in cell-based systems. We employed genetic code expansion to site-specifically introduce noncanonical amino acids with reactive groups in C-C chemokine receptor 5 (CCR5) near an allosteric binding site for the drug maraviroc. We then used molecular dynamics simulations to design heterobifunctional maraviroc analogues consisting of a drug fragment connected by a flexible linker to a reactive moiety capable of undergoing a bioorthogonal coupling reaction. We synthesized a library of these analogues and employed the bioorthogonal inverse electron demand Diels-Alder reaction to couple the analogues to the engineered CCR5 in live cells, which were then assayed using cell-based signaling assays. Tetherable low-affinity maraviroc fragments displayed an increase in potency for CCR5 engineered with reactive unnatural amino acids that were adjacent to the maraviroc binding site. The strategy we describe to tether novel drug fragments to GPCRs should prove useful to probe allosteric or cryptic binding site functionality in fragment-based GPCR-targeted drug discovery.
- 22 February 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (5) , 854-865
Route Optimization of the Non-covalent Modulator of Hemoglobin PF-07059013 for the Treatment of Sickle Cell Disease, Part I: From Discovery Synthesis to First Kilogram-Scale Manufacture
- 22 February 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (5) , 854-865
Route Optimization of the Non-covalent Modulator of Hemoglobin PF-07059013 for the Treatment of Sickle Cell Disease, Part I: From Discovery Synthesis to First Kilogram-Scale Manufacture
- Top Cited PapersOpen Access
- 1 June 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (12) , 8208-8226
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron). A sensitized high-throughput screen was used to identify 5-fluoropyrimidine-based GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nanomolar potency. Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron. Danuglipron increased insulin levels in primates but not rodents, which was explained by receptor mutagensis studies and a cryogenic electron microscope structure that revealed a binding pocket requiring a primate-specific tryptophan 33 residue. Oral administration of danuglipron to healthy humans produced dose-proportional increases in systemic exposure (NCT03309241). This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health.
- 1 June 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (12) , 8208-8226
Top Cited PapersOpen AccessA Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron). A sensitized high-throughput screen was used to identify 5-fluoropyrimidine-based GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nanomolar potency. Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron. Danuglipron increased insulin levels in primates but not rodents, which was explained by receptor mutagensis studies and a cryogenic electron microscope structure that revealed a binding pocket requiring a primate-specific tryptophan 33 residue. Oral administration of danuglipron to healthy humans produced dose-proportional increases in systemic exposure (NCT03309241). This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health.
- Open Access
A small-molecule oral agonist of the human glucagon-like peptide-1 receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection. Here we describe the first effective, orally bioavailable small molecule GLP-1R agonists. A sensitized high-throughput screen identified a series of small molecule GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nM potency. These small molecule agonists increased insulin levels in primates but not rodents, which is explained by a cryo-EM structure that revealed a binding pocket requiring primate-specific tryptophan 33. Importantly, oral administration of agonist PF-06882961 to healthy humans produced dose-dependent declines in serum glucose ( NCT03309241 ). This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health. One Sentence Summary: PF-06882961 is an orally administered small molecule that activates the GLP-1 receptor to lower blood glucose in humans.
Open AccessA small-molecule oral agonist of the human glucagon-like peptide-1 receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection. Here we describe the first effective, orally bioavailable small molecule GLP-1R agonists. A sensitized high-throughput screen identified a series of small molecule GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nM potency. These small molecule agonists increased insulin levels in primates but not rodents, which is explained by a cryo-EM structure that revealed a binding pocket requiring primate-specific tryptophan 33. Importantly, oral administration of agonist PF-06882961 to healthy humans produced dose-dependent declines in serum glucose ( NCT03309241 ). This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health. One Sentence Summary: PF-06882961 is an orally administered small molecule that activates the GLP-1 receptor to lower blood glucose in humans.